What Does the Evidence Say About BPC-157 Safety for Women?

Small human pilots of BPC-157 reported no short-term side effects, including a pilot in 12 women treated for severe bladder pain, and animal toxicity tests found no harm to organs. That pattern is reassuring, but it does not prove safety for women who inject BPC-157 for injury recovery, because no large trials have tested that use in women.

What have human studies seen so far?

Researchers tested an oral form called PL 14736 in small mid-stage ulcerative colitis trials, which study a condition that causes bowel inflammation. Those trials reported no side effects, and toxicology work never reached a lethal dose Sikiric review.

Three other small pilots looked at an injection into the knee joint for chronic pain, an intravenous dose to see how the body handles the drug, and injections into the bladder wall in 12 women with ongoing bladder pain. None reported short-term side effects narrative review clinic pilot summary. All were very small and followed people for a short time, so rare or longer-term effects would not show up.

Why doesn't that prove safety for recovery use in women?

A 2025 systematic review found that animal safety studies showed no harm across several organ systems, but it found no clinical safety data in people systematic review. There is still no published phase 2 or phase 3 trial of injections under the skin in healthy adults, which is the form women use most for recovery.

Results from swallowing the drug for bowel inflammation do not tell you how your body responds to an injection for a tendon or muscle injury. The route changes how much drug reaches the blood and how the immune system sees it, so oral findings do not transfer to injections.

What safety questions do regulators still raise?

The Food and Drug Administration said compounded drugs containing BPC-157 may pose a risk for immunogenicity for certain routes of administration, which means the immune system may react to the drug differently depending on how you take it. The agency also cited complexities with peptide-related impurities and verification of the active ingredient, which means difficulty making sure compounded vials contain pure and correctly identified drug FDA safety list. BPC-157 now appears in the withdrawn section after its nomination was withdrawn.

Reviewers conclude that BPC-157 should stay investigational until larger trials test safety and benefit in people narrative review.